SCHEMBL14633971

SCHEMBL14633971

Cc1ccc2c(-c3cnc(Nc4ccc(C)c(S(C)(=O)=O)c4)nc3N)n[nH]c2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SGK1 O00141 3/20 0.39
ABCB11 O95342 1/20 0.38
ITK Q08881 7/20 0.37
MAP2K4 P45985 2/20 0.36
JAK3 P52333 3/20 0.36
JAK1 P23458 2/20 0.36
BTK Q06187 1/20 0.36
CLK4 Q9HAZ1 2/20 0.36
CHEK1 O14757 1/20 0.36
PRKD3 O94806 1/20 0.36
CDK8 P49336 1/20 0.36
LIMK1 P53667 1/20 0.36
ROCK1 Q13464 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
KDR P35968 2/20 0.36
PLK4 O00444 1/20 0.35
AURKA O14965 1/20 0.35
PDPK1 O15530 1/20 0.35
DAPK3 O43293 1/20 0.35
JAK2 O60674 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14634241 0.90 KDR (0.40) ABCB11JAK3JAK1BTKCLK4
SCHEMBL2466308 0.88 GRM4 (0.41) SGK1ABCB11ITKJAK3JAK1
SCHEMBL2468759 0.86 NTRK1 (0.44) ABCB11ITKMAP2K4JAK3BTK
SCHEMBL14634243 0.86 SGK1 (0.40) SGK1ABCB11JAK3JAK1BTK
SCHEMBL14633684 0.85 ITK (0.37) SGK1ITKMAP2K4JAK3JAK1
SCHEMBL14633591 0.83 MEN1 (0.39) SGK1ABCB11JAK3JAK1CHEK1
SCHEMBL14633720 0.83 CDK2 (0.39) SGK1ABCB11ITKJAK3BTK
SCHEMBL2472742 0.83 JAK2 (0.40) SGK1ABCB11ITKJAK3JAK1
SCHEMBL2468378 0.81 CDK1 (0.39) ABCB11ITKJAK3JAK1CLK4
SCHEMBL14634281 0.81 CDK1 (0.39) SGK1ABCB11ITKJAK3JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US claimed
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023532-A1 INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS MAP3K19, MAP3K1, MAP3K20 SGK1 546/4885ABCB11 3476/4885ITK 339/4885
US-20130023534-A1 PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS CDK2, MAP3K19, MAP3K1 SGK1 841/4885ABCB11 4525/4885ITK 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.